

# Philip J Mease

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/46684/publications.pdf>

Version: 2024-02-01

81  
papers

6,867  
citations

117625

34  
h-index

66911

78  
g-index

82  
all docs

82  
docs citations

82  
times ranked

5454  
citing authors

#	ARTICLE	IF	CITATIONS
1	Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis. <i>Rheumatology</i> , 2023, 62, 606-616.	1.9	6
2	Suspecting and Diagnosing the Patient with Spondyloarthritis and What to Expect from Therapy. <i>Rheumatic Disease Clinics of North America</i> , 2022, 48, 507-521.	1.9	4
3	Potential Impact of Sex and BMI on Response to Therapy in Psoriatic Arthritis: Post Hoc Analysis of Results From the SEAM-PsA Trial. <i>Journal of Rheumatology</i> , 2022, 49, 885-893.	2.0	12
4	Challenges in the Diagnosis and Assessment of Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2022, , jrheum.211337.	2.0	0
5	Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials. <i>RMD Open</i> , 2022, 8, e002049.	3.8	8
6	P258â€¦Secukinumab Improves Physical Function and Inhibits Structural Damage in Psoriatic Arthritis PsA Patients With Sustained Remission or Low Disease Activity: Results From a Phase 3 Study. <i>Rheumatology</i> , 2022, 61, .	1.9	0
7	P260â€¦Secukinumab in Patients With Psoriatic Arthritis and Axial Manifestations: Predictors of Response From the Double-blind, Randomised, Phase 3b MAXIMISE Trial. <i>Rheumatology</i> , 2022, 61, .	1.9	0
8	P266â€¦Secukinumab provides clinical improvements in patients with active oligoarticular psoriatic arthritis: results from a pooled analysis of five phase 3 studies. <i>Rheumatology</i> , 2022, 61, .	1.9	0
9	Descriptive Comparisons of the Effect of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: The Corona Psoriatic Arthritis/Spondyloarthritis Registry Results. <i>Journal of Rheumatology</i> , 2021, 48, 693-697.	2.0	10
10	Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 312-320.	0.9	131
11	Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 185-193.	0.9	79
12	Suspecting and Diagnosing the Patient with Spondyloarthritis and What to Expect from Therapy. <i>Medical Clinics of North America</i> , 2021, 105, 325-339.	2.5	3
13	Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies. <i>Rheumatology</i> , 2021, 60, 5337-5350.	1.9	18
14	Comparison of Men and Women With Axial Spondyloarthritis in the US-based Corona Psoriatic Arthritis/Spondyloarthritis Registry. <i>Journal of Rheumatology</i> , 2021, 48, 1528-1536.	2.0	44
15	Pain in Axial Spondyloarthritis: More to It Than Just Inflammation. <i>Journal of Rheumatology</i> , 2021, 48, 1632-1634.	2.0	3
16	Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1147-1157.	0.9	43
17	Personal Experiences with Diagnostic Delay Among Axial Spondyloarthritis Patients: A Qualitative Study. <i>Rheumatology and Therapy</i> , 2021, 8, 1015-1030.	2.3	9
18	Primary care physician perspectives on screening for axial spondyloarthritis: A qualitative study. <i>PLoS ONE</i> , 2021, 16, e0252018.	2.5	6

#	ARTICLE	IF	CITATIONS
19	Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study. <i>RMD Open</i> , 2021, 7, e001600.	3.8	18
20	Secukinumab Efficacy on Psoriatic Arthritis GRAPPA-OMERACT Core Domains in Patients with or Without Prior Tumor Necrosis Factor Inhibitor Use: Pooled Analysis of Four Phase 3 Studies. <i>Rheumatology and Therapy</i> , 2021, 8, 1223-1240.	2.3	6
21	Axial involvement in psoriatic arthritis: An update for rheumatologists. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 880-887.	3.4	48
22	Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1. <i>Rheumatology and Therapy</i> , 2021, 8, 1789-1808.	2.3	14
23	Patient perspectives on health care provider practices leading to an axial spondyloarthritis diagnosis: an exploratory qualitative research study. <i>BMC Family Practice</i> , 2021, 22, 251.	2.9	5
24	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 88-93.	0.9	63
25	Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations. <i>Pain</i> , 2020, 161, 2446-2461.	4.2	64
26	Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. <i>Lancet, The</i> , 2020, 395, 1496-1505.	13.7	178
27	Guselkumab in biologic-naïve patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2020, 395, 1126-1136.	13.7	206
28	Clinical, Economic, and Humanistic Burden Associated With Delayed Diagnosis of Axial Spondyloarthritis: A Systematic Review. <i>Rheumatology and Therapy</i> , 2020, 7, 65-87.	2.3	62
29	Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis. <i>Rheumatology International</i> , 2020, 40, 1021-1028.	3.0	3
30	Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting. <i>Rheumatology International</i> , 2019, 39, 1547-1558.	3.0	5
31	Revised chronic widespread pain criteria: development from and integration with fibromyalgia criteria. <i>Scandinavian Journal of Pain</i> , 2019, 20, 77-86.	1.3	50
32	Comparative Disease Burden in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from Two Corrona Registries. <i>Rheumatology and Therapy</i> , 2019, 6, 529-542.	2.3	23
33	Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor. <i>Journal of Rheumatology</i> , 2019, 46, 475-482.	2.0	31
34	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 872-878.	0.9	36
35	Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1). <i>Journal of Rheumatology</i> , 2018, 45, 367-377.	2.0	102
36	GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e23-e23.	0.9	16

#	ARTICLE	IF	CITATIONS
37	Trial Characteristics as Contextual Factors When Evaluating Targeted Therapies in Patients With Psoriatic Disease: A Meta-€Epidemiologic Study. <i>Arthritis Care and Research</i> , 2018, 70, 1206-1217.	3.4	4
38	Considerations for the definition of remission criteria in psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 786-796.	3.4	38
39	Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 79-87.	0.9	454
40	Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. <i>Rheumatology</i> , 2017, 56, 1498-1509.	1.9	78
41	Fibromyalgia, a missed comorbidity in spondyloarthritis: prevalence and impact on assessment and treatment. <i>Current Opinion in Rheumatology</i> , 2017, 29, 304-310.	4.3	92
42	International Treatment Recommendations Update: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 684-685.	2.0	4
43	Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , 2017, 44, 697-700.	2.0	42
44	Performance of 3 Enthesitis Indices in Patients with Peripheral Spondyloarthritis During Treatment with Adalimumab. <i>Journal of Rheumatology</i> , 2017, 44, 599-608.	2.0	39
45	Frequency of Axial Spondyloarthritis Diagnosis Among Patients Seen by US Rheumatologists for Evaluation of Chronic Back Pain. <i>Arthritis and Rheumatology</i> , 2016, 68, 1669-1676.	5.6	71
46	2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 319-329.	3.4	1,173
47	Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. <i>Nature Reviews Rheumatology</i> , 2016, 12, 743-750.	8.0	71
48	Do Biologic-treated Psoriatic Arthritis Patients with Spondylitis Respond Differently with or without Concomitant Methotrexate from Patients without Spondylitis?. <i>Journal of Rheumatology</i> , 2016, 43, 471-473.	2.0	2
49	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1060-1071.	5.6	726
50	Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2016, 43, 343-349.	2.0	17
51	Clinical Remission in Patients with Active Psoriatic Arthritis Treated with Adalimumab and Correlations in Joint and Skin Manifestations. <i>Journal of Rheumatology</i> , 2015, 42, 952-959.	2.0	14
52	Biologic Therapy for Psoriatic Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 723-738.	1.9	52
53	Development of Criteria to Distinguish Inflammatory from Noninflammatory Arthritis, Enthesitis, Dactylitis, and Spondylitis: A Report from the GRAPPA 2013 Annual Meeting. <i>Journal of Rheumatology</i> , 2014, 41, 1249-1251.	2.0	24
54	Patient Participation in Psoriasis and Psoriatic Arthritis Outcome Research: A Report from the GRAPPA 2013 Annual Meeting. <i>Journal of Rheumatology</i> , 2014, 41, 1206-1211.	2.0	13

#	ARTICLE	IF	CITATIONS
55	GRAPPA 2013 Annual Meeting, Rheumatology Updates: Psoriatic Arthritis (PsA) Biomarker Project, Arthritis Mutilans, PsA-Peripheral Spondyloarthritis Epidemiology Project. Journal of Rheumatology, 2014, 41, 1244-1248.	2.0	5
56	Effective management of psoriasis and psoriatic arthritis: Insights on current and emerging therapies and enhanced professional collaboration. Seminars in Arthritis and Rheumatism, 2014, 44, e7-e8.	3.4	4
57	Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis. Drugs, 2014, 74, 423-441.	10.9	209
58	Psoriasis and Psoriatic Arthritis Educational Initiatives: An Update from the 2013 GRAPPA Annual Meeting. Journal of Rheumatology, 2014, 41, 1240-1243.	2.0	7
59	Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European/North American dermatology clinics. Journal of the American Academy of Dermatology, 2014, 71, 649-655.	1.2	55
60	Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. Journal of the American Academy of Dermatology, 2013, 69, 729-735.	1.2	397
61	Milnacipran combined with pregabalin in fibromyalgia: a randomized, open-label study evaluating the safety and efficacy of adding milnacipran in patients with incomplete response to pregabalin. Therapeutic Advances in Musculoskeletal Disease, 2013, 5, 113-126.	2.7	25
62	Pharmacotherapy of fibromyalgia. Best Practice and Research in Clinical Rheumatology, 2011, 25, 285-297.	3.3	56
63	Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthrit. Arthritis Care and Research, 2011, 63, S64-85.	3.4	277
64	Toward Development of a Fibromyalgia Responder Index and Disease Activity Score: OMERACT Module Update. Journal of Rheumatology, 2011, 38, 1487-1495.	2.0	60
65	Epidemiologic Evaluation of Cardiovascular Risk in Patients Receiving Milnacipran, Venlafaxine, or Amitriptyline: Evidence from French Health Data. Annals of Pharmacotherapy, 2011, 45, 179-188.	1.9	7
66	Psoriatic Arthritis: Pharmacotherapy Update. Current Rheumatology Reports, 2010, 12, 272-280.	4.7	11
67	Efficacy and Safety of Retreatment in Patients with Rheumatoid Arthritis with Previous Inadequate Response to Tumor Necrosis Factor Inhibitors: Results from the SUNRISE Trial. Journal of Rheumatology, 2010, 37, 917-927.	2.0	115
68	Safety, Tolerability, and Clinical Outcomes after Intraarticular Injection of a Recombinant Adeno-associated Vector Containing a Tumor Necrosis Factor Antagonist Gene: Results of a Phase 1/2 Study. Journal of Rheumatology, 2010, 37, 692-703.	2.0	99
69	Psoriatic arthritis - update on pathophysiology, assessment, and management. Bulletin of the NYU Hospital for Joint Diseases, 2010, 68, 191-8.	0.7	9
70	Assessing the Impact of Psoriatic Arthritis on Patient Function and Quality of Life: Lessons Learned from Other Rheumatologic Conditions. Seminars in Arthritis and Rheumatism, 2009, 38, 320-335.	3.4	26
71	Alefacept with methotrexate for treatment of psoriatic arthritis: Open-label extension of a randomized, double-blind, placebo-controlled study. Journal of the American Academy of Dermatology, 2009, 60, 402-411.	1.2	40
72	Further Strategies for Treating Fibromyalgia: The Role of Serotonin and Norepinephrine Reuptake Inhibitors. American Journal of Medicine, 2009, 122, S44-S55.	1.5	40

#	ARTICLE	IF	CITATIONS
73	Pharmacotherapy of Fibromyalgia. <i>Rheumatic Disease Clinics of North America</i> , 2009, 35, 359-372.	1.9	26
74	Fibromyalgia: Key Clinical Domains, Comorbidities, Assessment, And Treatment. <i>CNS Spectrums</i> , 2009, 14, 6-9.	1.2	11
75	Fibromyalgia: Should the treatment paradigm be monotherapy or combination pharmacotherapy?. <i>Current Pain and Headache Reports</i> , 2008, 12, 399-405.	2.9	19
76	Spondyloarthritis update: new insights regarding classification, pathophysiology, and management. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , 2008, 66, 203-9.	0.7	11
77	Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: Results of a randomized, double-blind, placebo-controlled study. <i>Arthritis and Rheumatism</i> , 2006, 54, 1638-1645.	6.7	141
78	Psoriatic arthritis therapy advances. <i>Current Opinion in Rheumatology</i> , 2005, 17, 426-432.	4.3	21
79	Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2005, 52, 3279-3289.	6.7	828
80	Fibromyalgia syndrome. <i>Journal of Rheumatology</i> , 2005, 32, 2270-7.	2.0	129
81	Current treatment of psoriatic arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2003, 29, 495-511.	1.9	12